The once-daily human GLP-1 analogue liraglutide impacts appetite and energy intake in patients with type 2 diabetes after short-term treatment
The once-daily human GLP-1 analogue liraglutide impacts appetite and energy intake in patients with type 2 diabetes after short-term treatment
复制标题
DOI：
10.1111/dom.12108
复制
发表时间：
2013-10-01
影响因子：
5.8
通讯作者：
Zdravkovic, M.
中科院分区：
文献类型：
--
作者：
Flint, A.;Kapitza, C.;Zdravkovic, M.
目的是在一项随机、安慰剂对照、双盲、交叉研究中，研究利拉鲁肽对食欲和能量摄入的影响。18名2型糖尿病患者被分配到每天一次皮下注射利拉鲁肽(每周增加0.6毫克)或安慰剂治疗3周。在5小时的膳食测试中，使用视觉模拟标尺评估食欲评分。在随后的自由午餐期间也测量了能量和常量营养素的摄入量。3周后，服用利拉鲁肽1.8 mg的患者餐后平均饥饿评分和最低饥饿评分显著低于安慰剂(p
The aim was to investigate effects of liraglutide on appetite and energy intake in a randomized, placebo-controlled, double-blind, crossover study. Eighteen subjects with type 2 diabetes were assigned to treatment with once-daily subcutaneous liraglutide (increasing by weekly 0.6mg increments) or placebo for 3weeks. Appetite ratings were assessed using visual analogue scales during a 5-h meal test. Energy and macronutrient intake during the subsequent ad libitum lunch were also measured. After 3 weeks, mean postprandial and minimum hunger ratings were significantly lower with liraglutide 1.8mg than placebo (p